MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar GreenCollegeGrad (76.55) Submitted: 3/9/2011 9:16:20 PM : Outperform Start Price: $3.79 MNKD Score: -56.26

MannKind corporation, a S+P four star rated stock, is awaiting the FDA to approve its star in the making, an inhaled insulin named Afrezza. Though biotech can be risky this play is certainly worth taking a gamble on, especially when S+P rates a fair value at 5.50 and a "consider selling" price at 11. Gonna hve to reccomend this one

Report this Post Reply

Featured Broker Partners


Advertisement